Press release
Pancreatic Ductal Adenocarcinoma Pipeline Analysis, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharm
DelveInsight's, "Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2025," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.According to DelveInsight, over 80 companies are actively developing more than 80 therapies for Pancreatic Ductal Adenocarcinoma.
Pancreatic Ductal Adenocarcinoma Overview:
Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive cancers, with a 5-year survival rate below 10%. Most patients are diagnosed at advanced, locally unresectable, or metastatic stages. The poor prognosis is driven by the disease's complex, multifactorial nature. Early detection is difficult, as symptoms often appear only after the cancer has progressed and spread. Treatment is further complicated by genetic and cellular factors, with significant tumor mutations causing gene instability that promotes tumor growth and therapy resistance.
Download our report @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Therapeutics Market.
Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
DelveInsight's Pancreatic Ductal Adenocarcinoma (PDAC) pipeline report highlights a dynamic landscape with over 80 companies actively developing more than 80 therapies for PDAC.
Recent regulatory developments include:
*
March 26, 2025: FDA approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors, based on Phase 3 CABINET study data.
*
December 4, 2024: FDA approval of zenocutuzumab for NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma.
*
June 2024: FDA granted Fast Track designation to IBI343 for advanced or metastatic PDAC.
Key players advancing PDAC therapies include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others. Promising pipeline candidates in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, among others.
Pancreatic Ductal Adenocarcinoma Pipeline Analysis
The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.
*
Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:
*
Stage of development
*
Pancreatic Ductal Adenocarcinoma Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Pancreatic Ductal Adenocarcinoma Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Pancreatic Ductal Adenocarcinoma Licensing agreements
*
Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Pancreatic Ductal Adenocarcinoma Emerging Drugs
*
Onvansertib: Cardiff Oncology
*
Nadunolimab: Cantargia
*
Zimberelimab: Arcus Biosciences
Pancreatic Ductal Adenocarcinoma Companies
More than 80 companies are developing therapies for Pancreatic Ductal Adenocarcinoma, with XOMA among those advancing candidates into the Phase III stage.
DelveInsight's report covers around 140+ products under different phases of Pancreatic Ductal Adenocarcinoma clinical trials like
*
Pancreatic Ductal Adenocarcinoma Late stage Therapies (Phase III)
*
Pancreatic Ductal Adenocarcinoma Mid-stage Therapies (Phase II)
*
Pancreatic Ductal Adenocarcinoma Early-stage Therapies (Phase I)
*
Pancreatic Ductal Adenocarcinoma Pre-clinical and Pancreatic Ductal Adenocarcinoma Discovery stage Therapies
*
Pancreatic Ductal Adenocarcinoma Discontinued & Inactive Therapies
Pancreatic Ductal Adenocarcinoma pipeline report provides the Pancreatic Ductal Adenocarcinoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Ductal Adenocarcinoma Therapies and Key Pancreatic Ductal Adenocarcinoma Companies: Pancreatic Ductal Adenocarcinoma Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment
- Pancreatic Ductal Adenocarcinoma Assessment by Product Type
- Pancreatic Ductal Adenocarcinoma By Stage
- Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
Download Pancreatic Ductal Adenocarcinoma Sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ Pancreatic Ductal Adenocarcinoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns
4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)
7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Ductal Adenocarcinoma Discontinued Products
13. Pancreatic Ductal Adenocarcinoma Product Profiles
14. Pancreatic Ductal Adenocarcinoma Key Companies
15. Pancreatic Ductal Adenocarcinoma Key Products
16. Dormant and Discontinued Products
17. Pancreatic Ductal Adenocarcinoma Unmet Needs
18. Pancreatic Ductal Adenocarcinoma Future Perspectives
19. Pancreatic Ductal Adenocarcinoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pancreatic Ductal Adenocarcinoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-ductal-adenocarcinoma-pipeline-analysis-2025-by-delveinsight-cardiff-oncology-xoma-alphamab-cantargia-renovorx-syntrix-biosystems-eucure-biopharma-panbela-therapeutics-jeil-pharm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Ductal Adenocarcinoma Pipeline Analysis, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharm here
News-ID: 4168809 • Views: …
More Releases from ABNewswire

ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approval …
DelveInsight's, "ALK+ NSCLC Pipeline Insight 2025" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK+ NSCLC pipeline landscape. It covers the ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…

Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Amyotrophic…

NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…

RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA A …
DelveInsight's, "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Pancreatic
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…